François Laliberté

analysis group inc.

H指数:31

被引数:3,783

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Assessment of Healthcare Resource Utilization-Defined Manic and Depressive Events Among Patients with Bipolar I Disorder Treated with Cariprazine Versus Aripiprazole

真实世界评估卡巴拉品与阿立哌唑治疗I型双相障碍患者中，基于医疗资源利用定义的躁狂和抑郁事件

Advances in Therapy

IF4

2026-08-170

Burden of chronic oral corticosteroids among adults with asthma in the United States

美国哮喘成人中慢性口服糖皮质激素的负担

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: GLOBAL

IF0

2026-05-011

Mepolizumab Demonstrates Quantifiable Reduction in Corticosteroid-Related Adverse Effects in Severe Asthma

Mepolizumab在重症哮喘中显示出可量化的糖皮质激素相关不良反应的减少。

annals of allergy, asthma & immunology

IF0

2026-04-030

PRE

Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world

在现实世界中患有遗传性血管性水肿的美国患者中，berotralstat启动后的发作率降低

allergy, asthma & clinical immunology

IF0

2026-01-250

OAAI

FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up from Dual Therapy Stratified by Exacerbations and Prior Dual Therapy: A Subgroup Analysis of a Comparative Effectiveness Study

Advances in Therapy

IF4

2026-01-190

OAAI

Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma

美泊利单抗对重症哮喘儿童和青少年患者的真实世界影响

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY: GLOBAL

IF0

2026-01-010

OAAI

Economic impact of using cariprazine as the first versus subsequent adjunctive therapy for Medicaid beneficiaries with major depressive disorder

使用卡立派嗪作为 Medicaid 受益人中重度抑郁症患者的一线与二线附加治疗的经济影响

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-12-310

PRE

Real-World Health Care Resource Utilization and Costs Among Patients with Activated Phosphoinositide 3-Kinase Delta (PI3Kδ) Syndrome in the United States

美国活化磷脂酰肌醇3-激酶δ(PI3Kδ)综合征患者的实际医疗资源利用及费用

Advances in Therapy

IF4

2025-10-080

Exacerbation Reduction in Patients with Asthma Following Escalation to FF/UMEC/VI from ICS/LABA: Retrospective Cohort Study

PULMONARY THERAPY

IF3

2025-10-010

OAAI

Comparative Effectiveness of FF/UMEC/VI and BUD/GLY/FORM in Patients with COPD Stepping Up From Dual Therapy

比较FF/UMEC/VI与BUD/GLY/FORM在从双重疗法升级治疗的COPD患者中的疗效

Advances in Therapy

IF4

2025-07-070

Health care resource utilization and costs associated with switching versus augmenting antidepressant monotherapy in second-line treatment of major depressive disorder

重度抑郁症二线治疗中，与加量相比切换抗抑郁药单药治疗相关的医疗资源利用及成本

Journal of Affective Disorders

IF4.9

2025-07-020

Effectiveness and safety of rivaroxaban versus warfarin in patients with pulmonary embolism and right ventricular dysfunction: a retrospective cohort study

利伐沙班与华法林在肺栓塞合并右心室功能不全患者中的有效性与安全性：一项回顾性队列研究

Research and Practice in Thrombosis and Haemostasis

IF3.4

2025-06-010

OAAI

Characterizing the Journey of Early Alzheimer's Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study

在美国接受LeCanemab治疗的患者中早期阿尔茨海默病的病程特征：一项真实世界证据研究

NEUROLOGY AND THERAPY

IF4.8

2025-05-040

Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS)

APDS（激活的磷脂酰肌醇3-激酶δ综合征）患者的总生存率

ORPHANET JOURNAL OF RARE DISEASES

IF3.5

2025-05-030

The real-world impact of cariprazine on short- and long-term disability outcomes among commercially insured patients in the United States

卡利拉嗪对美国商业保险患者短期和长期残疾结局的实际影响

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-02-190

Healthcare resource utilization and costs of using cariprazine as the first versus subsequent adjunctive therapy for major depressive disorder

重度抑郁症患者使用卡利拉赞作为初始与后续增效剂治疗时的医疗资源利用及成本

JOURNAL OF MEDICAL ECONOMICS

IF3

2025-02-010

Impact of cariprazine on body weight and blood pressure among adults with bipolar I disorder, schizophrenia, or major depressive disorder in a real-world setting

general psychiatry

IF3.1

2025-01-270

OAAI

Comparative Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol and Budesonide/Glycopyrrolate/Formoterol Fumarate among US Patients with Chronic Obstructive Pulmonary Disease

ADVANCES IN THERAPY

IF4

2024-12-280

OAAI

Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI)

ADVANCES IN THERAPY

IF4

2024-12-230

OAAI

Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data

ADVANCES IN THERAPY

IF4

2024-12-051

OAAI

François Laliberté

个人简介

教育背景

工作经历

荣誉奖项

研究方向